Monoclonal Antibodies

Dupixent (dupilumab) is used to treat certain patients with eczema, prurigo nodularis (PN), chronic spontaneous urticaria (CSU), bullous pemphigoid (BP), asthma, chronic obstructive pulmonary disease (COPD), nasal polyps (NP) and eosinophilic esophagitis (EOE). There is currently no generic alternative to Dupixent. It may be covered by your Medicare or insurance plan.

ROMOSOZUMAB prevents and treats osteoporosis. It works by making your bones stronger and less likely to break (fracture). It is a monoclonal antibody.

BRODALUMAB treats psoriasis. It works by slowing down an overactive immune system. It is a monoclonal antibody.

TEZEPELUMAB prevents and treats the symptoms of asthma. It works by decreasing inflammation of the airways, making it easier to breathe. It is prescribed when other asthma medications have not worked well enough. Do not use it to treat a sudden asthma attack. It is a monoclonal antibody.

UBLITUXIMAB treats multiple sclerosis (MS). It works by slowing down an overactive immune system, which prevents or delays worsening symptoms. It also decreases the number of flare-ups. It is not a cure for MS. It is a monoclonal antibody.

SATRALIZUMAB treats neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the nerves of the eyes and spinal cord. It works by decreasing inflammation. It is a monoclonal antibody.

CRIZANLIZUMAB prevents the symptoms of sickle cell disease, such as pain crises and acute chest syndrome. It works by preventing blood cells from clumping together. This increases blood flow and the amount of oxygen that gets to your tissues. It is a monoclonal antibody.

Andembry is only available as a brand name drug.

Arzerra (ofatumumab) is an expensive drug used to treat leukemia. It is slightly more popular than comparable drugs. Arzerra is currently only available as a brand drug.

Bamlanivimab is an investigational monoclonal antibody therapy authorized for emergency use by the FDA to treat COVID-19. It is not yet FDA approved, and the safety and effectiveness of this therapy is still being evaluated.

AVELUMAB treats some types of cancer. It works by helping your immune system slow or stop the spread of cancer cells. It is a monoclonal antibody.

CAPLACIZUMAB treats acquired thrombotic thrombocytopenic purpura (aTTP), a condition that causes blood clots and low levels of platelets in the body. It works by preventing blood cells (platelets) from clumping together to form a clot. It is a monoclonal antibody.

Casirivimab is an investigational monoclonal antibody therapy authorized for emergency use by the FDA to treat COVID-19. It must be administered together with imdevimab. It is not yet FDA approved, and the safety and effectiveness of this therapy is still being evaluated.

BUROSUMAB treats low phosphorus levels caused by a tumor or genetic condition. It works increasing levels of phosphorus in your body. This makes your bones stronger and less likely to break (fracture). It is a monoclonal antibody.

NAXITAMAB treats neuroblastoma, a cancer that occurs in nerve cells. It works by slowing down the growth of cancer cells. It is a monoclonal antibody.

DARATUMUMAB treats multiple myeloma, a type of bone marrow cancer. It works by helping your immune system slow or stop the spread of cancer cells. It is a monoclonal antibody.

Darzalex Faspro (daratumumab/hyaluronidase-fihj) is used to treat multiple myeloma. There are currently no generic alternatives to darzalex faspro. It may be covered by your Medicare or insurance plan, but some pharmacy coupons or cash prices could help offset the cost.

ELOTUZUMAB treats multiple myeloma, a type of bone marrow cancer. It works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells. It is a monoclonal antibody.

Emrelis is part of the Monoclonal Antibodies class and treats Lung Cancer. Monoclonal antibodies are used to treat many conditions, including cancers, autoimmune diseases, and certain infections. They are similar to the antibodies in the body's immune system. But they are lab-made to have a specific target based on the condition they treat. Targets can include cancer cells, viruses, immune cells, and certain receptors in the body. Emrelis is only available as a brand name drug.

SUTIMLIMAB treats cold agglutinin disease, an autoimmune condition that breaks down red blood cells in the body. It works by stopping the breakdown of red blood cells, which reduces the need for blood transfusions. It is a monoclonal antibody.

Etesevimab is an investigational monoclonal antibody therapy authorized for emergency use by the FDA to treat COVID-19. It is not yet FDA approved, and the safety and effectiveness of this therapy is still being evaluated.

Evusheld (tixagevimab/cilgavimab) is approved under an emergency use authorization (EUA) for the prevention of COVID-19. Evusheld is only available as a brand drug. It may be covered by your Medicare or insurance plan, but some pharmacy coupons or cash prices could help offset the cost.

Fasenra (benralizumab) is used to prevent the symptoms of asthma. Fasenra is a monoclonal antibody and works to target proteins. Fasena is avalible as an autoinjector and a syringe. There are currently no generic alternatives for Fasenra. It is covered by some medicare and insurance plans.

EMAPALUMAB treats hemophagocytic lymphohistiocytosis (HLH), a condition that can cause severe inflammation and tissue injury in the body. It works by slowing down an overactive immune system. This decreases inflammation. It is a monoclonal antibody.